Clodronate : a review of its use in the prevention of bone metastases and the management of skeletal complications associated with bone metastases in patients with breast cancer.
Clodronate (clodronate disodium, Bonefos) is a non-nitrogen-containing bisphosphonate that inhibits osteoclast activity, and thereby inhibits bone resorption. Clodronate has been extensively used in patients with advanced breast cancer, and is generally well tolerated. In patients with primary breast cancer, clodronate is currently the only bisphosphonate shown to improve survival rates and to reduce the incidence of bone metastases in randomised controlled trials. Further trials in patients with early breast cancer are warranted to confirm results to date and to determine the optimal duration of treatment, as well as the efficacy of the drug compared with other bisphosphonates. In the meantime, clodronate is a well established bisphosphonate which has shown beneficial effects in the prevention of bone metastases and on survival in patients with primary breast cancer.
Dando
Toni M
TM
Adis International Limited, Auckland, New Zealand. demail@adis.co.nz
Wiseman
Lynda R
LR
D001859:Bone Neoplasms / Q000453:epidemiology / Q000517:prevention & control* / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D004002:Clodronic Acid / Q000627:therapeutic use*; D019468:Disease Management; D006801:Humans
D004002:Clodronic Acid